EFFICACY OF BRENTUXIMAB VEDOTIN AND OTHER TREATMENTS IN PATIENTS WITH RELAPSED OR REFRACTORY (RR) SYSTEMIC ANAPLASTIC LARGE-CELL LYMPHOMA (SALCL): A SYSTEMATIC REVIEW

被引：0
|
作者：
Hamashima, C. [1 ]
Ogoshi, K. [2 ]
Okamoto, M. [3 ]
Shabana, M. [4 ]
Kishimoto, T. [3 ]
Fukao, A. [5 ]
机构：
[1] Natl Canc Ctr Japan, Tokyo, Japan
[2] Niigata Canc Ctr Hosp, Niigata, Japan
[3] Tottori Univ, Yonago, Tottori, Japan
[4] San in Rosai Hosp, Yonago, Tottori, Japan
[5] Yamagata Univ, Yamagata 990, Japan
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 07期
关键词：
D O I：
10.1016/j.jval.2013.08.417
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A395 / A395
页数：1
相关论文
共 50 条
  • [21] ACTIVITY OF BRENTUXIMAB VEDOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA OR SYSTEMIC ANAPLASTIC LARGE-CELL LYMPHOMA: COMPARISONS WITH META-ANALYSES OF HISTORICAL CHEMOTHERAPY DATA
    Gualberto, A.
    Chi, A. X.
    Liu, Y.
    HAEMATOLOGICA, 2012, 97 : 82 - 83
  • [22] HEALTH STATE UTILITIES FOR RELAPSED/REFRACTORY (REL/REF) HODGKIN LYMPHOMA (HL) AND SYSTEMIC ANAPLASTIC LARGE-CELL LYMPHOMA (SALCL)
    Swinburn, P.
    Shingler, S.
    Liu, Y.
    Huang, H.
    Acaster, S.
    HAEMATOLOGICA, 2012, 97 : 82 - 82
  • [23] Efficacy of Brentuximab Vedotin and Nivolumab in Refractory or Relapsed Hodgkin Lymphoma: A Systematic Review
    Macapagal, Sharina C.
    Lee, Hayoung
    Jabbar, Javaria Abdul
    Fjorden, Anna Caroline
    Joseph, Irene Tresa
    Kaur, Ramanpreet
    Mostafa, Jihan A.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (03)
  • [24] Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotin
    Chihara, Dai
    Wong, Shannon
    Feldman, Tatyana
    Fanale, Michelle A.
    Sanchez, Larysa
    Connors, Joseph M.
    Savage, Kerry J.
    Oki, Yasuhiro
    HEMATOLOGICAL ONCOLOGY, 2019, 37 (01) : 35 - 38
  • [25] Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review
    Donato, Eva M.
    Fernandez-Zarzoso, Miguel
    Antonio Hueso, Jose
    de la Rubia, Javier
    ONCOTARGETS AND THERAPY, 2018, 11 : 4583 - 4590
  • [26] BRENTUXIMAB VEDOTIN PLUS CHP IN FRONTLINE SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA (SALCL): ADJUSTED ESTIMATES OF EFFICACY AND COST-EFFECTIVENESS REMOVING THE EFFECTS OF RETREATMENT WITH BRENTUXIMAB VEDOTIN
    Cranmer, H.
    Trueman, D.
    Woodcock, F.
    Evers, E.
    Podkonjak, T.
    VALUE IN HEALTH, 2020, 23 : S431 - S431
  • [27] The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
    Senter, Peter D.
    Sievers, Eric L.
    NATURE BIOTECHNOLOGY, 2012, 30 (07) : 631 - 637
  • [28] Phase I/II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma
    Ogura, Michinori
    Tobinai, Kensei
    Hatake, Kiyohiko
    Ishizawa, Kenichi
    Uike, Naokuni
    Uchida, Toshiki
    Suzuki, Tatsuya
    Aoki, Tomohiro
    Watanabe, Takashi
    Maruyama, Dai
    Yokoyama, Masahiro
    Takubo, Takatoshi
    Kagehara, Hideaki
    Matsushima, Takafumi
    CANCER SCIENCE, 2014, 105 (07) : 840 - 846
  • [29] The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
    Peter D Senter
    Eric L Sievers
    Nature Biotechnology, 2012, 30 : 631 - 637
  • [30] Cutaneous Anaplastic Large-Cell Lymphoma with Dramatic Response to Brentuximab Vedotin
    Sahin, Mustafa
    Miskioglu, Mine
    Inanir, Isil
    Akar, Hikmet
    Nese, Nalan
    Temiz, Peyker
    Aydogdu, Ismet
    TURKISH JOURNAL OF HEMATOLOGY, 2021, 38 (01) : 85 - 87
12345